The regulatory landscape for peptides changes frequently. Here's an honest breakdown of where the most popular peptides stand.
The regulatory status of peptides in the US is genuinely complicated — and it shifts. Here's an honest overview of where the most commonly prescribed peptides stand as of 2024–2025, and what it means practically for patients.
This is for informational purposes only. Regulatory status changes frequently. Always consult a licensed physician and confirm current status with your clinic before starting any protocol.
In the US, peptides exist in one of several regulatory buckets:
Commercial versions (Ozempic, Wegovy, Mounjaro, Zepbound) are FDA-approved. Compounded versions were widely available during commercial shortages but FDA has signaled tighter restrictions as shortages resolve. Status: legal to compound under shortage guidance; patients should confirm current availability.
Previously FDA-approved (Geref) but voluntarily withdrawn from market. Remains compoundable as an active pharmaceutical ingredient. Widely prescribed by anti-aging and longevity physicians. Generally considered to have a stable regulatory status.
Neither FDA-approved nor on an established bulk compounding list. FDA has included these on "Category 2" bulk substance lists under review. Many clinics prescribe them; some have moved to sermorelin or tesamorelin as more established alternatives. Status: actively discussed, variable by state.
FDA placed BPC-157 and TB-500 on its Category 2 bulk substances list (under review, not approved for compounding). Some compounding pharmacies have stopped producing them while others continue. Regulatory status is the most uncertain of the commonly prescribed peptides. Confirm with your clinic's pharmacy before starting.
Both have established compounding pathways. NAD+ is widely used in IV therapy with no significant regulatory challenges. Thymosin Alpha-1 (Zadaxin) has FDA orphan drug designation and is compoundable. Generally stable regulatory status.
For most patients, the practical implication is: ask your clinic how they stay current on regulatory status and what they do when a compound's status changes. Quality clinics monitor FDA guidance actively and will proactively switch you to an equivalent if a compound is restricted. Clinics that don't track this are a liability.
The best protection: stick with 503A/503B compounding pharmacies. They operate within the regulatory framework and will not supply compounds that lack proper legal status to do so — they have their licenses to protect.